This is the seventh indication application for sacituzumab tirumotecan (sac-TMT) and the second application for the ADC plus IO combination regimen of sac-TMT plus pembrolizumab accepted for review.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results